2024年度我国脑胶质瘤领域研究进展

Research Progress of Glioma in China in 2024

  • 摘要: 脑胶质瘤是成人中枢神经系统最常见的原发性恶性肿瘤。即使采用手术联合放化疗标准治疗后,高级别胶质瘤患者的预后仍不佳,亟待深入探究其发生发展机制,开发新的治疗方案。本文梳理了2024年度我国脑胶质瘤领域最新研究进展,涵盖肿瘤发生发展机制、肿瘤免疫微环境构成、胶质瘤成像技术与新显像剂研发、手术方案改进、放化疗抵抗机制,以及新型治疗方案的探索。这些研究为推动脑胶质瘤临床诊疗水平提升,提供了坚实的理论基础,有望为改善患者预后带来新契机。

     

    Abstract: Glioma is the most common primary malignant tumor of the central nervous system in adults. Despite the standard treatment of surgery combined with radiotherapy and chemotherapy, the prognosis for high-grade glioma patients remains poor, highlighting the urgent need to further explore its pathogenesis and develop new therapeutic strategies. This article reviews the research progress in the field of glioma in China in 2024, covering tumorigenesis mechanisms, tumor immune microenvironment composition, advances in imaging techniques and novel imaging agents, improvements in surgical approaches, mechanisms of radio- and chemoresistance, and explorations of new therapeutic modalities. These studies provide a solid theoretical foundation for advancing clinical diagnosis and treatment of gliomas and may offer new opportunities to improve patient outcomes.

     

/

返回文章
返回